Petros Pharmaceuticals PTPI

$ 0.29 -5.67%

Quarterly report 2024-Q3
added 11-13-2024

Petros Pharmaceuticals Balance Sheet 2011-2024 | PTPI

Annual Balance Sheet Petros Pharmaceuticals

	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
Net Debt	-13 M	-9.02 M	-23.3 M	-9.96 M	11.6 M	-	-	-	-	-	-	-	-
Long Term Debt	138 K	263 K	405 K	-	7.06 M	-	-	-	-	-	-	-	-
Long Term Debt Current	125 K	142 K	126 K	-	-	-	-	-	-	-	-	-	-
Total Non Current Liabilities	-	-	-	601 K	9.24 M	-	-	-	-	-	-	-	-
Total Current Liabilities	10.8 M	7.07 M	31 M	-	-	-	-	-	-	-	-	-	-
Total Liabilities	21.3 M	15.7 M	31.8 M	52.4 M	50.3 M	-	-	-	-	-	-	-	-
Deferred Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-
Retained Earnings	-98.9 M	-90.7 M	-70.7 M	-	-41.1 M	-	-	-	-	-	-	-	-
Total Assets	33.8 M	32.4 M	67.4 M	69.9 M	58.4 M	-	-	-	-	-	-	-	-
Cash and Cash Equivalents	13.3 M	9.43 M	23.8 M	17.1 M	-	-	-	-	-	-	-	-	-
Book Value	12.5 M	16.7 M	35.5 M	17.5 M	8.02 M	-	-	-	-	-	-	-	-
Total Shareholders Equity	12.1 M	16.7 M	35.5 M	17.5 M	-	-	-	-	-	-	-	-	-

All numbers in USD currency

Quarterly Balance Sheet Petros Pharmaceuticals

	2024-Q3	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
Long Term Debt	-	-	-	-	151 K	183 K	224 K	263 K	300 K	336 K	371 K	405 K	438 K	470 K	501 K	531 K	531 K	-	531 K	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Non Current Liabilities	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Liabilities	17.6 M	16 M	19.6 M	21.3 M	31.9 M	15.8 M	15.1 M	15.7 M	17 M	16.8 M	20.1 M	31.8 M	34.2 M	37.2 M	45.2 M	52.4 M	52.4 M	-	52.4 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Deferred Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Retained Earnings	-104 M	-102 M	-101 M	-98.9 M	-99.2 M	-94.7 M	-92.1 M	-90.7 M	-86.5 M	-72.7 M	-70.9 M	-70.7 M	-62.5 M	-60.8 M	-58.7 M	-61.7 M	-61.7 M	-	-61.7 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Assets	20.7 M	25.2 M	30.3 M	33.8 M	38.9 M	28.7 M	30.6 M	32.4 M	37.7 M	51 M	55.9 M	67.4 M	52 M	56.7 M	66.2 M	69.9 M	69.9 M	-	69.9 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Cash and Cash Equivalents	3.9 M	7.5 M	11.1 M	13.3 M	18 M	7.38 M	8.32 M	9.43 M	11.2 M	13.3 M	17.7 M	23.8 M	8.14 M	11 M	14.6 M	17.1 M	17.1 M	832 K	17.1 M	2.15 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Book Value	3.12 M	9.19 M	10.7 M	12.5 M	7.06 M	12.9 M	15.4 M	16.7 M	20.7 M	34.2 M	35.7 M	35.5 M	17.8 M	19.5 M	20.9 M	17.5 M	17.5 M	-	17.5 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Shareholders Equity	3.12 M	8.07 M	9.79 M	12.1 M	6.93 M	12.9 M	15.4 M	16.7 M	20.7 M	34.2 M	35.7 M	35.5 M	17.8 M	19.5 M	20.9 M	17.5 M	17.5 M	-3.83 M	17.5 M	8.02 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency